• 1
    Balch CM, Soong S, Milton GW, Shaw HM, McGovern VJ, Murad TM, et al. A comparison of prognostic factors and surgical resultsin 1,786 patients with localized (stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 1982; 196: 677-84.
  • 2
    Belli F, Mascheroni L, Cascinelli N. Potential role of interferons in the treatmnet of metastatic melanoma. In: MaioM, editor. Immunology of human melanoma. Bruxelles: IOS Press, 1996: 217-26.
  • 3
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14: 7-17.
  • 4
    Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987; 14(2(S2)): 1-12.
  • 5
    Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, et al. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 1984; 77: 427-32.
  • 6
    Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103: 32-6.
  • 7
    Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252: 938-41.
  • 8
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672-6.
  • 9
    Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA. Central nervos system toxicity of intereferon. Br J Cancer 1983; 47: 419-22.
  • 10
    Adams F, Fernanadez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6: 355-9.
  • 11
    Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26: 596-600.
  • 12
    Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon-related cortical blindness. Cancer Chemother Pharmacol 1992; 29: 329-30.
  • 13
    Hagberg H, Blomkvist E, Ponten U, Persson L, Muhr C, Eriksson B, et al. Does alpha-interferon in conjunction with radiotherapy increase the risk of complications in the central nervous system. Ann Oncol 1990; 1: 449-51.
  • 14
    Forman AD. Neurologic complication of cytokine therapy. Oncology 1994; 8: 105-10.
  • 15
    Mattson K, Niiranen A, Iivanainen M, Farkkila M, Bergstrom I, Holsti LR, et al. Neurotoxicity of interferon. Cancer Treat Rep 1983; 67: 958-61.
  • 16
    Meyers CA, Obbens E, Scheibel RS, Moser RP. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991; 68: 88-92.
  • 17
    Fahn S, Marsden CD, Calne DB. Recent developments in Parkinson's Disease. Florham Park: MacMillian Health Care Information, 1987:153-63, 293-304.
  • 18
    Overall JE, Hollister LE, Pichot P. Major psychiatric disorders. A four dimensional model. Arch Gen Psychiatry 1967; 16: 146.
  • 19
    Spinler H, Tognoni G. Standardizzazione e taratura Italiana di test neuropsicologici Ital J Neurol Sci 1987;6(S 8).
  • 20
    De Santi G, Menini R. Manuale del test AIT di R. Meili. Firenze: Organizzazioni Speciali, 1981.
  • 21
    Pinco. Manuale di diagnostica psicologica. Firenze: Giunti, 1967.
  • 22
    Zazzo R. Manuel pour l'examen pychologique de l'enfant. Neuchatel: Delachaux et Niestlé, 1969.
  • 23
    Spielberger CD. Manual for the state-trait anxiety inventory. Palo Alto: Consulting Psychologists Press, 1983.
  • 24
    Tamburini M, Rosso S, Gamba A, Mencaglia E, De Conno F, Ventafridda V. A therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol 1992; 3: 565-70.
  • 25
    Mattews JNS, Altman DG, Campbel MJ, Royston P. Analysis of serial measurement in medical research. BMJ 1990; 300: 230-5.
  • 26
    Lehman EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
  • 27
    Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39: 13-6.
  • 28
    Bruera E, Miller MJ, Macmillan K, Kuhen N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48: 163-6.
  • 29
    Girotti F, Carella F, Grassi MP, Soliveri P, Marano R, Caraceni T. Motor and cognitive performaces of Parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry 1986; 49: 657-60.
  • 30
    Cassileth BR, Knuiman MW, Abeloff MD, Falkson G, Ezdinli EZ, Mehta CR. Anxiety levels in patients randomized to adjuvant therapy versus observation for early breast cancer. J Clin Oncol 1986; 4: 972-4.
  • 31
    Ventafridda V, DeConno F, Ripamonti C, Gamba A, Tamburini M. Quality of life assessment during a palliative care program. Ann Oncol 1990; 1: 415-20.